The present invention relates to a composition for drug delivery to a tissue having a tight junction comprising a triolein emulsion of an internal water phase/oil phase/external water phase (Water/Oil/Water, W/O/W) structure in which oil droplet comprises triolein and water droplets are enclosed in the oil droplet, as an active ingredient, and a method of preparing the same, and the triolein emulsion of the W/O/W-type structure according to the present invention has excellent safety because it retains the BBB opening activity of triolein as it is and the water droplets are enclosed in the oil droplets and contain surfactants and can further enclose fat-soluble drugs in the oil droplets and thus it can more effectively deliver drugs to tissues having tight junctions such as the brain, testicles, and retina.

The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

Suggested is a cosmetic blend, comprising or consisting of (a) at least one TRPV1 and/or TRPV3 modulator and (b1) at least one 1,2-alkandiol having 5 to 12 carbon atoms and/or (b2) at least one polyol having 3 to 12 carbon atoms and 3 to 6 hydroxyl groups.

The present invention generally relates to microfluidic droplets and, in particular, to multiple emulsion microfluidic droplets. In certain aspects, particles such as gel particles can be prepared in an aqueous carrier from aqueous droplets (or a non-aqueous carrier from non-aqueous droplets). For example, in some embodiments, double-emulsion droplets of a first fluid, surrounded by a second fluid, contained in a carrier fluid may be prepared, where the first fluid forms a gel and the second fluid is removed. For instance, the second fluid may be dissolved in the carrier fluid, or the second fluid may be hardened, then removed, for example, due to a change in pH. Other embodiments of the present invention are generally directed to kits containing such microfluidic droplets, microfluidic devices for making such microfluidic droplets, or the like.

The present invention generally relates to microfluidic droplets and, in particular, to multiple emulsion microfluidic droplets. In certain aspects, particles such as gel particles can be prepared in an aqueous carrier from aqueous droplets (or a non-aqueous carrier from non-aqueous droplets). For example, in some embodiments, double-emulsion droplets of a first fluid, surrounded by a second fluid, contained in a carrier fluid may be prepared, where the first fluid forms a gel and the second fluid is removed. For instance, the second fluid may be dissolved in the carrier fluid, or the second fluid may be hardened, then removed, for example, due to a change in pH. Other embodiments of the present invention are generally directed to kits containing such microfluidic droplets, microfluidic devices for making such microfluidic droplets, or the like.

Provided are an oral delivery composition including oxaliplatin, a water-soluble anticancer agent, and a preparation method thereof, including forming an ionic complex with a bile acid derivative, which is an oral absorption promoter, and oxaliplatin, and incorporating it into the inner aqueous phase of a water-in-oil-in-water (w/o/w) multiple nanoemulsions, thereby obtaining the oral delivery composition with improved oral bioavailability of oxaliplatin, a water-soluble anticancer agent, avoiding the inconvenience and problems of injection, improving patient compliance, and reducing medical costs.

Provided are an oral delivery composition including oxaliplatin, a water-soluble anticancer agent, and a preparation method thereof, including forming an ionic complex with a bile acid derivative, which is an oral absorption promoter, and oxaliplatin, and incorporating it into the inner aqueous phase of a water-in-oil-in-water (w/o/w) multiple nanoemulsions, thereby obtaining the oral delivery composition with improved oral bioavailability of oxaliplatin, a water-soluble anticancer agent, avoiding the inconvenience and problems of injection, improving patient compliance, and reducing medical costs.

Methods for treating inflammatory bowel disease are provided, comprising administration of glatiramer acetate in a sustained-release depot form and administration of adipose-derived stem cells.

Methods for treating inflammatory bowel disease are provided, comprising administration of glatiramer acetate in a sustained-release depot form and administration of adipose-derived stem cells.